Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing ...
Zacks Investment Research on MSN2d
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top EstimatesMonte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ...
Zacks Investment Research on MSN3d
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue EstimatesImmunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago. These figures are ...
After hours: March 20 at 7:51:13 PM EDT Loading Chart for MYNZ ...
Mit unserem Forum zur Mainz Biomed BV-Aktie bleiben Sie mit Diskussionen und Kommentaren am Puls der marktrelevanten Entwicklungen über das Unternehmen Mainz Biomed BV (MYNZ). Alle Kommentare ...
1 Day MYNZ 12.41% DJIA -0.03% Russell 2K -0.65% Health Care/Life Sciences 0.04% ...
After hours: 19 March at 7:28:16 pm GMT-4 Loading Chart for MYNZ ...
B41-Gensingen (ots) - Am Donnerstag gegen 18:20 Uhr kam es auf der B41 in der Auffahrt zur A61 zu einem Verkehrsunfall. Ein 33-jähriger Bad Kreuznacher befuhr die B41 aus Richtung Bad Kreuznach ...
Experts discuss how cancer treatment and survivorship can be made more equitable and affordable through advocacy, outreach, and effective communication tools. Beyond Cancer: Caring for Young ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback